CRSP
NASDAQ
CH
CRISPR Therapeutics AG - Common Shares
$49.51
▲ +$0.70
(+1.43%)
Vol 1.7M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$5.0B
ROE
-26.4%
Margin
-1273.7%
D/E
0.00
Beta
1.73
52W
$30–$78
Wall Street Consensus
35 analysts · Apr 20269
Strong Buy
13
Buy
12
Hold
1
Sell
0
Strong Sell
62.9%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.17 | $-1.37 | $-0.20 |
| Sep 2025 | $-1.28 | $-1.17 | +$0.11 |
| Jun 2025 | $-1.45 | $-1.29 | +$0.16 |
| Mar 2025 | $-1.28 | $-1.58 | $-0.30 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $35.0M | — | — | — | — |
| Net Income | -$37.3M | -$136.0M | -$208.5M | -$106.4M | -$130.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -25.2% | -25.2% | -25.2% | -25.2% | -26.4% | -26.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -23379.9% | -1229.4% | -1229.4% | -1229.4% | -1273.7% | -1273.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 16.61 | 16.61 | 16.61 | 16.61 | 16.22 | 16.22 |
Key Ratios
ROA (TTM)
-22.5%
P/S (TTM)
130.36
P/B
1.7
EPS (TTM)
$-5.58
CF/Share
$-4.22
Rev Growth 3Y
-65.6%
52W High
$78.48
52W Low
$30.04
$30.04
52-Week Range
$78.48
Financial Health
Free Cash Flow
-$93.1M
Net Debt
-$140.8M
Cash
$347.6M
Total Debt
$206.7M
As of Dec 31, 2025
How does CRSP compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CRSP valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
130.4
▲
914%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
1.7
▼
29%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CRSP profitability vs Biotechnology peers
ROE
-26.4%
▲
61%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-1273.7%
▼
344%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-22.5%
▲
52%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
CRSP financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
16.2
▲
265%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.7
▲
79%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CRSP fundamentals radar
CRSP
Peer median
Industry
CRSP profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio